Zoledronic acid

Generic Name: Zoledronic acid

Brand Names: Aclasta, Reclast, Zometa, Zoledronic Acid Accord, Zoledronic acid Actavis, Zoledronic acid medac, Zoledronic acid Teva, Zoledronic Acid Hospira, Zoledronic acid Mylan

Drug Type: Small Molecule

Chemical Formula: C_₅H_₁₀N_₂O_₇P_₂

CAS Number: 118072-93-8

Unique Ingredient Identifier: 70HZ18PH24

Background: Zoledronic acid, or CGP 42'446, is a third generation, nitrogen containing bisphosphonate similar to ibandronic acid, minodronic acid, and risedronic acid. Zoledronic acid is used to treat and prevent multiple forms of osteoporosis, hypercalcemia of malignancy, multiple myeloma, bone metastases from solid tumors, and Paget’s disease of bone. Zoledronic acid was first described in the literature in 1994.

Zoledronic acid was granted FDA approval on 20 August 2001.

Indication: Zoledronic acid is indicated to treat hypercalcemia of malignancy, multiple myeloma, bone metastases from solid tumors, osteoporosis in men and postmenopausal women, glucocorticoid induced osteoporosis, and Paget's disease of bone in men and women. Zoledronic acid is also indicated for the prevention of osteoporosis in post menopausal women and glucocorticoid induced osteoporosis.

Associated Conditions: Bone Metastases, Hypercalcemia of Malignancy, Multiple Myeloma (MM), Osteoporosis, Osteoporosis caused by Glucocorticoid Treatment, Paget's Disease of Bone, Paget’s Disease

Associated Therapies: Bone Mineral Density

Clinical Trials

Comparing a Single-Dose vs. Twice Yearly Zoledronate in Patients With Early Stage Breast Cancer (REaCT-ZOL)

Phase 4

Active, not recruiting

Conditions: Early-stage Breast Cancer

Interventions: Drug: Zoledronate

First Posted Date: 2018-09-10

Last Posted Date: 2025-03-24

Lead Sponsor: Ottawa Hospital Research Institute

Target Recruit Count: 211

Registration Number: NCT03664687

Locations: 🇨🇦
William Osler Health System, Brampton Civic Hospital, Brampton, Ontario, Canada
🇨🇦
Juravinski Cancer Centre, Hamilton, Ontario, Canada
🇨🇦
Kingston Health Sciences Centre, Kingston, Ontario, Canada

and more 3 locations

Pilot Study for Zoledronic Acid to Prevent Bone Loss After Bariatric Surgery

Phase 4

Completed

Conditions: Bariatric Surgery Candidate

Interventions: Drug: Zoledronic Acid
Dietary Supplement: Calcium citrate + vitamin D
Dietary Supplement: Vitamin D3

First Posted Date: 2018-02-06

Last Posted Date: 2021-04-29

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 6

Registration Number: NCT03424239

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Bisphosphonates for Prevention of Post-Denosumab Bone Loss

Phase 2

Completed

Conditions: IOP
Osteoporosis

Interventions: Drug: Alendronate
Drug: Zoledronic Acid

First Posted Date: 2018-01-10

Last Posted Date: 2024-05-08

Lead Sponsor: Columbia University

Target Recruit Count: 24

Registration Number: NCT03396315

Locations: 🇺🇸
Columbia University Medical Center, New York, New York, United States
🇺🇸
Creighton University, Omaha, Nebraska, United States

Neoadjuvant Zoledronate and Atorvastatin in Triple Negative Breast Cancer

Phase 2

Completed

Conditions: Triple Negative Breast Cancer

Interventions: Drug: Standard neoadjuvant cht
Drug: Zoledronate
Drug: Atorvastatin 80mg

First Posted Date: 2017-11-30

Last Posted Date: 2023-10-19

Lead Sponsor: Mario Negri Institute for Pharmacological Research

Target Recruit Count: 54

Registration Number: NCT03358017

Locations: 🇮🇹
Azienda Socio Sanitaria Territoriale ASST Monza - Ospedale S. Gerardo, Monza, Italy
🇮🇹
Azienda Socio Sanitaria Territoriale ASST Lariana - Presidio Ospedaliero Ospedale S. Anna, San Fermo della Battaglia, Como, Italy
🇮🇹
Azienda Socio Sanitaria Territoriale - ASST Papa Giovanni XXIII, Bergamo, Italy

and more 6 locations

Luteinizing Hormone-releasing Hormone Analogue and Enzalutamide +/- Zoledronic Acid in Prostate Cancer Patients

Phase 2

Completed

Conditions: Prostate Cancer
Bone Metastases

Interventions: Drug: Enzalutamide
Drug: Zoledronic Acid

First Posted Date: 2017-11-08

Last Posted Date: 2024-08-01

Lead Sponsor: Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia

Target Recruit Count: 126

Registration Number: NCT03336983

Locations: 🇮🇹
Azienda Ospedaliera Spedali Civili di Brescia, Brescia, Italy

Efficacy of Zoledronic Acid in Osteoporosis of Children With Multiple Disabilities

Completed

Conditions: Osteoporosis
Multiple Disability

Interventions: Drug: Zoledronic Acid

First Posted Date: 2017-10-04

Last Posted Date: 2017-10-04

Lead Sponsor: Central Hospital, Nancy, France

Target Recruit Count: 60

Registration Number: NCT03301285

Locations: 🇫🇷
Children's Hospital - CHRU de Nancy, Vandoeuvre les nancy, France

Local Bisphosphonate Effect on Recurrence Rate in Extremity Giant Cell Tumor of Bone

Phase 3

Recruiting

Conditions: Giant Cell Tumor of Bone

Interventions: Drug: Zoledronic Acid

First Posted Date: 2017-09-28

Last Posted Date: 2024-10-08

Lead Sponsor: St. Louis University

Target Recruit Count: 120

Registration Number: NCT03295981

Locations: 🇺🇸
University of Washington, Seattle, Washington, United States
🇺🇸
University of California - Los Angeles, Los Angeles, California, United States
🇺🇸
Johns Hopkins University Hospital, Baltimore, Maryland, United States

and more 13 locations